Logo image of MNOV

MEDICINOVA INC (MNOV) Stock Fundamental Analysis

NASDAQ:MNOV - Nasdaq - US58468P2065 - Common Stock - Currency: USD

1.51  +0.04 (+2.72%)

Fundamental Rating

3

Taking everything into account, MNOV scores 3 out of 10 in our fundamental rating. MNOV was compared to 567 industry peers in the Biotechnology industry. While MNOV has a great health rating, there are worries on its profitability. MNOV does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year MNOV has reported negative net income.
In the past year MNOV has reported a negative cash flow from operations.
MNOV had negative earnings in each of the past 5 years.
In the past 5 years MNOV always reported negative operating cash flow.
MNOV Yearly Net Income VS EBIT VS OCF VS FCFMNOV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

Looking at the Return On Assets, with a value of -19.78%, MNOV is in the better half of the industry, outperforming 78.98% of the companies in the same industry.
MNOV's Return On Equity of -21.05% is amongst the best of the industry. MNOV outperforms 86.22% of its industry peers.
Industry RankSector Rank
ROA -19.78%
ROE -21.05%
ROIC N/A
ROA(3y)-17.22%
ROA(5y)-16.33%
ROE(3y)-18.28%
ROE(5y)-17.27%
ROIC(3y)N/A
ROIC(5y)N/A
MNOV Yearly ROA, ROE, ROICMNOV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10 -20 -30

1.3 Margins

MNOV does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MNOV Yearly Profit, Operating, Gross MarginsMNOV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800

More info and screens

8

2. Health

2.1 Basic Checks

MNOV does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MNOV has about the same amount of shares outstanding.
MNOV has more shares outstanding than it did 5 years ago.
There is no outstanding debt for MNOV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
MNOV Yearly Shares OutstandingMNOV Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
MNOV Yearly Total Debt VS Total AssetsMNOV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

An Altman-Z score of 2.21 indicates that MNOV is not a great score, but indicates only limited risk for bankruptcy at the moment.
MNOV has a Altman-Z score of 2.21. This is in the better half of the industry: MNOV outperforms 74.03% of its industry peers.
There is no outstanding debt for MNOV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.21
ROIC/WACCN/A
WACC10.04%
MNOV Yearly LT Debt VS Equity VS FCFMNOV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M 80M

2.3 Liquidity

A Current Ratio of 13.88 indicates that MNOV has no problem at all paying its short term obligations.
With an excellent Current ratio value of 13.88, MNOV belongs to the best of the industry, outperforming 87.99% of the companies in the same industry.
MNOV has a Quick Ratio of 13.88. This indicates that MNOV is financially healthy and has no problem in meeting its short term obligations.
MNOV has a Quick ratio of 13.88. This is amongst the best in the industry. MNOV outperforms 87.99% of its industry peers.
Industry RankSector Rank
Current Ratio 13.88
Quick Ratio 13.88
MNOV Yearly Current Assets VS Current LiabilitesMNOV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

1

3. Growth

3.1 Past

MNOV shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -27.78%.
The Revenue for MNOV has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)-27.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-50%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 11.64% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-121.74%
EPS Next 2Y-29.82%
EPS Next 3Y-21.05%
EPS Next 5Y11.64%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MNOV Yearly Revenue VS EstimatesMNOV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2023 2029 2030 2031 2032 200M 400M 600M 800M
MNOV Yearly EPS VS EstimatesMNOV Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 4 6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

MNOV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year MNOV is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MNOV Price Earnings VS Forward Price EarningsMNOV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MNOV Per share dataMNOV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

MNOV's earnings are expected to decrease with -21.05% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-29.82%
EPS Next 3Y-21.05%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MNOV!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MEDICINOVA INC

NASDAQ:MNOV (5/2/2025, 8:10:52 PM)

1.51

+0.04 (+2.72%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-19 2025-02-19/amc
Earnings (Next)05-08 2025-05-08
Inst Owners21.97%
Inst Owner Change0%
Ins Owners2.98%
Ins Owner Change0%
Market Cap74.07M
Analysts82.5
Price Target7.65 (406.62%)
Short Float %0.4%
Short Ratio11.94
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.5%
Min EPS beat(2)-6.95%
Max EPS beat(2)1.96%
EPS beat(4)2
Avg EPS beat(4)-1.08%
Min EPS beat(4)-17.65%
Max EPS beat(4)18.3%
EPS beat(8)6
Avg EPS beat(8)19.04%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-10%
PT rev (3m)-6.25%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-35.14%
EPS NY rev (3m)-108.33%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.41
P/tB 1.94
EV/EBITDA N/A
EPS(TTM)-0.23
EYN/A
EPS(NY)-0.51
Fwd EYN/A
FCF(TTM)-0.22
FCFYN/A
OCF(TTM)-0.22
OCFYN/A
SpS0
BVpS1.07
TBVpS0.78
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -19.78%
ROE -21.05%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-17.22%
ROA(5y)-16.33%
ROE(3y)-18.28%
ROE(5y)-17.27%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 4.27%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 13.88
Quick Ratio 13.88
Altman-Z 2.21
F-Score2
WACC10.04%
ROIC/WACCN/A
Cap/Depr(3y)53.06%
Cap/Depr(5y)91.84%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-27.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-50%
EPS Next Y-121.74%
EPS Next 2Y-29.82%
EPS Next 3Y-21.05%
EPS Next 5Y11.64%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-28.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-42.83%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-43.22%
OCF growth 3YN/A
OCF growth 5YN/A